EPR: Evidence and fallacy.
暂无分享,去创建一个
[1] Seiji Miura,et al. Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[2] N. Rapoport,et al. Effect of ultrasound on the permeability of vascular wall to nano-emulsion droplets. , 2013, Ultrasound in medicine & biology.
[3] J. Milam,et al. Posttraumatic growth, quality of life, and treatment symptoms among cancer chemotherapy outpatients. , 2013, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.
[4] E. Azzopardi,et al. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. , 2013, The Journal of antimicrobial chemotherapy.
[5] N. Takahashi,et al. Dense Accumulation of Lipiodol Emulsion in Hepatocellular Carcinoma Nodule during Selective Balloon-occluded Transarterial Chemoembolization: Measurement of Balloon-occluded Arterial Stump Pressure , 2013, CardioVascular and Interventional Radiology.
[6] Alexander T Florence,et al. "Targeting" nanoparticles: the constraints of physical laws and physical barriers. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[7] Joseph W. Nichols,et al. Odyssey of a cancer nanoparticle: from injection site to site of action. , 2012, Nano today.
[8] Francesco M Veronese,et al. State of the art in PEGylation: the great versatility achieved after forty years of research. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[9] Y. Barenholz. Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[10] B. Shoichet,et al. Colloidal Aggregation Affects the Efficacy of Anticancer Drugs in Cell Culture , 2012, ACS chemical biology.
[11] R. Jain,et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner , 2012, Nature nanotechnology.
[12] R. Sanson-Fisher,et al. Cancer Treatment Survey (CaTS): development and validation of a new instrument to measure patients' preparation for chemotherapy and radiotherapy , 2012, Psycho-oncology.
[13] Mauro Ferrari,et al. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[14] Yechezkel Barenholz,et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. , 2012, Nanomedicine : nanotechnology, biology, and medicine.
[15] Rakesh K Jain,et al. Delivery of molecular and cellular medicine to solid tumors. , 1997, Advanced drug delivery reviews.
[16] A. Hasenburg,et al. Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial) , 2011, BMC Cancer.
[17] H. Shim,et al. Molecular portraits of intratumoral heterogeneity in human ovarian cancer. , 2011, Cancer letters.
[18] R. Gatenby,et al. A multiscale model of the bone marrow and hematopoiesis. , 2011, Mathematical biosciences and engineering : MBE.
[19] Jun Fang,et al. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.
[20] Dai Fukumura,et al. Scaling rules for diffusive drug delivery in tumor and normal tissues , 2011, Proceedings of the National Academy of Sciences.
[21] R. Jain,et al. Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.
[22] Ick Chan Kwon,et al. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. , 2010, Journal of Controlled Release.
[23] Ming-Zher Poh,et al. Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. , 2010, Biophysical journal.
[24] Samir Mitragotri,et al. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. , 2010, Current pharmaceutical design.
[25] Z. Werb,et al. Tumors as organs: complex tissues that interface with the entire organism. , 2010, Developmental cell.
[26] Christine Allen,et al. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. , 2010, Molecular pharmaceutics.
[27] Hiroshi Maeda,et al. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. , 2010, Bioconjugate chemistry.
[28] Dai Fukumura,et al. Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre‐Clinical Models , 2010, Microcirculation.
[29] C. Allen,et al. Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[30] Robert K Prud'homme,et al. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy , 2009, Expert opinion on drug delivery.
[31] A. Bao,et al. [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. , 2009, Nuclear medicine and biology.
[32] E. Miele,et al. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer , 2009, International journal of nanomedicine.
[33] J. Ajani,et al. Docetaxel-related side effects and their management. , 2009, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[34] Ick Chan Kwon,et al. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[35] A. Ullrich,et al. Paul Ehrlich's magic bullet concept: 100 years of progress , 2008, Nature Reviews Cancer.
[36] Sung-Bae Kim,et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer , 2008, Breast Cancer Research and Treatment.
[37] P. Sonneveld,et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] D. Mutch,et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] S. Pun,et al. Increased nanoparticle penetration in collagenase-treated multicellular spheroids , 2007, International journal of nanomedicine.
[40] K. Tanabe,et al. Cancer immunoediting from immune surveillance to immune escape , 2007, Immunology.
[41] G. Melillo. Targeting hypoxia cell signaling for cancer therapy , 2007, Cancer and Metastasis Reviews.
[42] Khaled Greish,et al. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines , 2007, Journal of drug targeting.
[43] M. Kanematsu,et al. Lipiodol retention and massive necrosis after lipiodol-chemoembolization of hepatocellular carcinoma: Correlation between computed tomography and histopathology , 1993, CardioVascular and Interventional Radiology.
[44] J. Carlsson,et al. Penetration of substances into tumor tissue—A methodological study on cellular spheroids , 1981, In Vitro.
[45] S. Tosatti,et al. Biomedical interfaces: titanium surface technology for implants and cell carriers. , 2006, Nanomedicine.
[46] Volker Wagner,et al. The emerging nanomedicine landscape , 2006, Nature Biotechnology.
[47] M J Hawkins,et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] D. Groothuis,et al. Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors. , 2006, Neuro-oncology.
[49] M. Dewhirst,et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. , 2006, Journal of the National Cancer Institute.
[50] R. Rifkin,et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma , 2006, Cancer.
[51] David Schrama,et al. Antibody targeted drugs as cancer therapeutics , 2006, Nature Reviews Drug Discovery.
[52] Nicholas A Peppas,et al. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.
[53] Michael Hawkins,et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Michael Levi. Classic Kaposi's sarcoma. , 2005, Journal of the American Podiatric Medical Association.
[55] Y. Bae,et al. Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice , 2005, Journal of drug targeting.
[56] C. de Lange Davies,et al. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx™) in human osteosarcoma xenografts , 2005, British Journal of Cancer.
[57] M. Flessner,et al. Resistance of Tumor Interstitial Pressure to the Penetration of Intraperitoneally Delivered Antibodies into Metastatic Ovarian Tumors , 2005, Clinical Cancer Research.
[58] E. Rofstad,et al. Comparison of tumor blood perfusion assessed by dynamic contrast‐enhanced MRI with tumor blood supply assessed by invasive imaging , 2005, Journal of magnetic resonance imaging : JMRI.
[59] Chiming Wei,et al. The pathway to commercialization for nanomedicine. , 2005, Nanomedicine : nanotechnology, biology, and medicine.
[60] Y. Hiraku,et al. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. , 2005, Life sciences.
[61] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[62] C. Shapiro,et al. Cardiac safety of liposomal anthracyclines. , 2004, Seminars in oncology.
[63] D. Alberts,et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. , 2004, Seminars in oncology.
[64] S. Chan,et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[65] C. Davies,et al. Collagenase Increases the Transcapillary Pressure Gradient and Improves the Uptake and Distribution of Monoclonal Antibodies in Human Osteosarcoma Xenografts , 2004, Cancer Research.
[66] Jay W. Shin,et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma–associated herpesvirus , 2004, Nature Genetics.
[67] A. Santoro,et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] A. Bao,et al. Direct 99mTc Labeling of Pegylated Liposomal Doxorubicin (Doxil) for Pharmacokinetic and Non-Invasive Imaging Studies , 2004, Journal of Pharmacology and Experimental Therapeutics.
[69] Yechezkel Barenholz,et al. Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs , 1993, Pharmaceutical Research.
[70] Rakesh K. Jain,et al. Vascular and interstitial barriers to delivery of therapeutic agents in tumors , 1990, Cancer and Metastasis Reviews.
[71] H. Maeda,et al. A pharmacokinetic simulation model for chemotherapy of brain tumor with an antitumor protein antibiotic, neocarzinostatin , 1981, Cancer Chemotherapy and Pharmacology.
[72] J. Kopeček,et al. The Influence of Cytotoxicity of Macromolecules and of VEGF Gene Modulated Vascular Permeability on the Enhanced Permeability and Retention Effect in Resistant Solid Tumors , 2004, Pharmaceutical Research.
[73] R. Jain,et al. Solid stress generated by spheroid growth estimated using a linear poroelasticity model. , 2003, Microvascular research.
[74] J. Verweij,et al. Pharmacological Effects of Formulation Vehicles , 2003, Clinical pharmacokinetics.
[75] Rakesh K Jain,et al. Molecular regulation of vessel maturation , 2003, Nature Medicine.
[76] Hans-Peter Lipp,et al. Toxicity of platinum compounds , 2003, Expert opinion on pharmacotherapy.
[77] Jun Fang,et al. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. , 2003, International immunopharmacology.
[78] J. M. Harris,et al. Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.
[79] Yechezkel Barenholz,et al. Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.
[80] D. McDonald,et al. Significance of blood vessel leakiness in cancer. , 2002, Cancer research.
[81] Saroja Ramanujan,et al. Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. , 2002, Biophysical journal.
[82] Terry L. Smith,et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] D. Keefe,et al. Anthracycline-induced cardiomyopathy. , 2001, Seminars in oncology.
[84] D Guthrie,et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] H. Maeda,et al. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[86] H. S. Oh,et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[87] R. B. Campbell,et al. Role of tumor–host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[88] R. Vile,et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[89] H. Maeda,et al. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. , 1991, Advanced drug delivery reviews.
[90] M. Bally,et al. A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form , 2001, Drug safety.
[91] R K Jain,et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[92] S. Weinbaum,et al. Starling forces that oppose filtration after tissue oncotic pressure is increased. , 2000, American journal of physiology. Heart and circulatory physiology.
[93] R. Jain,et al. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.
[94] M. Dewhirst,et al. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. , 2000, Cancer research.
[95] L. Guillou,et al. Benign lymphangioendothelioma (acquired progressive lymphangioma): a lesion not to be confused with well-differentiated angiosarcoma and patch stage Kaposi's sarcoma: clinicopathologic analysis of a series. , 2000, The American journal of surgical pathology.
[96] S. Groshen,et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[97] R K Jain,et al. Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.
[98] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[99] K. Maruyama,et al. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. , 1999, International journal of pharmaceutics.
[100] G. Yancopoulos,et al. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.
[101] R. Gillies,et al. Causes and effects of heterogeneous perfusion in tumors. , 1999, Neoplasia.
[102] D. Tzemach,et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes , 1999, Cancer.
[103] J Verweij,et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. , 1999, Cancer research.
[104] M. Newman,et al. Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs , 1999, Human & experimental toxicology.
[105] D. Devine,et al. Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. , 1998, Archives of biochemistry and biophysics.
[106] J. Ross,et al. The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, Stem cells.
[107] J. Pignon,et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. , 1998, Journal of hepatology.
[108] M A Fischl,et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[109] R. Jain,et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[110] S. Stewart,et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] D. Tzemach,et al. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals , 1997 .
[112] R. K. Jain,et al. Interstitial fluid pressure in intracranial tumours in patients and in rodents. , 1997, British Journal of Cancer.
[113] R K Jain,et al. Tumor angiogenesis and interstitial hypertension. , 1996, Cancer research.
[114] Dayan Ad. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl). , 1996 .
[115] J. V. Von Roenn,et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] P. Volberding,et al. Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma , 1996, Journal of clinical pharmacology.
[117] R. Skalak,et al. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. , 1995, Cancer research.
[118] A. Gabizon,et al. Liposome circulation time and tumor targeting: implications for cancer chemotherapy , 1995 .
[119] M. Boyd,et al. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen , 1995 .
[120] Y. Ichinose,et al. The correlation between tumor size and lymphatic vessel invasion in resected peripheral stage I non-small-cell lung cancer. A potential risk of limited resection. , 1994, The Journal of thoracic and cardiovascular surgery.
[121] R. Jain,et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.
[122] D. Ribatti,et al. Bone marrow angiogenesis and progression in multiple myeloma , 1994, British journal of haematology.
[123] Y. Barenholz,et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.
[124] Teruo Okano,et al. Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-Adriamycin conjugates , 1994 .
[125] M. Newman,et al. Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®) , 1994 .
[126] S. Horwitz. Taxol (paclitaxel): mechanisms of action. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[127] R Bicknell,et al. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. , 1993, Cancer research.
[128] M. Winterhalter,et al. Liposome stability and formation: experimental parameters and theories on the size distribution. , 1993, Chemistry and physics of lipids.
[129] E. Eisenhauer,et al. Clinical toxicities encountered with paclitaxel (Taxol). , 1993, Seminars in oncology.
[130] M. Gottesman. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. , 1993, Cancer research.
[131] Nandini V. Katre,et al. The conjugation of proteins with polyethylene glycol and other polymers: Altering properties of proteins to enhance their therapeutic potential , 1993 .
[132] R. Weiss. The anthracyclines: will we ever find a better doxorubicin? , 1992, Seminars in oncology.
[133] J. Weinstein,et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. , 1992, Cancer research.
[134] R K Jain,et al. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. , 1992, Cancer research.
[135] H. Maeda,et al. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. , 1992, Bioconjugate chemistry.
[136] K Messmer,et al. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. , 1992, Cancer research.
[137] A. Gabizon. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. , 1992, Cancer research.
[138] T. Konno. Targeting chemotherapy for hepatoma: arterial administration of anticancer drugs dissolved in Lipiodol. , 1992, European journal of cancer.
[139] L. Seymour. Passive tumor targeting of soluble macromolecules and drug conjugates. , 1992, Critical reviews in therapeutic drug carrier systems.
[140] K. Ulbrich,et al. Preclinical evaluation of polymer-bound doxorubicin , 1992 .
[141] A. Gabizon,et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[142] Harold E. Dvorak,et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels , 1991, The Journal of experimental medicine.
[143] R. Shoemaker,et al. Induction of multiple‐drug resistance during anti‐neoplastic chemotherapy in vitro , 1991, International journal of cancer.
[144] T M Allen,et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.
[145] H. Dvorak,et al. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. , 1991, Cancer cells.
[146] R. Jain,et al. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. , 1991, Cancer research.
[147] R K Jain,et al. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.
[148] P. Cullis,et al. Use of liposomes as injectable-drug delivery systems. , 1989, American journal of hospital pharmacy.
[149] A. Lunderquist,et al. In Vivo Microscopy of the Liver after Injection of Lipiodol into the Hepatic Artery and Portal Vein in the Rat , 1989, Acta radiologica.
[150] H. Maeda,et al. Cytotoxicity of smancs in comparison with other anticancer agents against various cells in culture. , 1989, Anticancer research.
[151] H. Dvorak,et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.
[152] A. Gabizon,et al. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[153] O. Matsui,et al. [Mechanism of lipiodol accumulation and retention in hepatic tumors--analysis in cases of simple lipiodol injection]. , 1987, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica.
[154] J. Levick. Flow through interstitium and other fibrous matrices. , 1987, Quarterly journal of experimental physiology.
[155] M. Fukuoka,et al. [Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity]. , 1987, Gan to kagaku ryoho. Cancer & chemotherapy.
[156] R K Jain,et al. Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.
[157] H. Maeda,et al. Anticancer effects of arterial administration of the anticancer agent SMANCS with lipiodol on metastatic lymph nodes , 1987, Cancer.
[158] R. Lipton,et al. Phase I clinical and pharmacokinetic study of taxol. , 1987, Cancer research.
[159] R. Kobayashi,et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. , 1987, The New England journal of medicine.
[160] H. Maeda,et al. [General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics]. , 1987, Gan to kagaku ryoho. Cancer & chemotherapy.
[161] I. Goldberg. Free radical mechanisms in neocarzinostatin-induced DNA damage. , 1987, Free radical biology & medicine.
[162] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[163] Y. Deugnier,et al. [Lipiodolized angiography in hepatocellular carcinomas. Contribution of iodine-131-labelled lipiodol]. , 1986, Journal de radiologie.
[164] R. Jain,et al. Microvascular permeability of normal and neoplastic tissues. , 1986, Microvascular research.
[165] H. Maeda,et al. [Stability of high molecular weight anticancer agent SMANCS and its transfer from oil-phase to water-phase. Comparative study with neocarzinostatin]. , 1986, The Japanese journal of antibiotics.
[166] M. Bally,et al. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. , 1985, Biochimica et biophysica acta.
[167] M. Ueda,et al. Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. , 1985, Journal of medicinal chemistry.
[168] R. Jain,et al. Effect of hyperthermia on microvascular permeability to macromolecules in normal and tumor tissues. , 1985, International journal of microcirculation, clinical and experimental.
[169] S. Tashiro,et al. Selective targeting of anti‐cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium , 1984, Cancer.
[170] S. W. O'Connor,et al. Accessibility of circulating immunoglobulin G to the extravascular compartment of solid rat tumors. , 1984, Cancer research.
[171] H. Maeda,et al. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. , 1984, Cancer research.
[172] Toshimitsu Konno,et al. Tailor-making of protein drugs by polymer conjugation for tumor targeting: A brief review on smancs , 1984 .
[173] K. Hasuo,et al. Selective effects of lipiodolized antitumor agents , 1984, Journal of surgical oncology.
[174] M. Hashida,et al. Macromolecule-drug conjugates in targeted cancer chemotherapy. , 1984, Critical reviews in therapeutic drug carrier systems.
[175] R K Jain,et al. Extravascular diffusion in normal and neoplastic tissues. , 1984, Cancer research.
[176] S. Tashiro,et al. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. , 1983, European journal of cancer & clinical oncology.
[177] T. Allen,et al. Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. , 1983, The Journal of pharmacology and experimental therapeutics.
[178] Patrick Couvreur,et al. Pharmacokinetics and Distribution of a Biodegradable Drug-carrier , 1983 .
[179] C. Presant,et al. Tumor-imaging potential of liposomes loaded with In-111-NTA: biodistribution in mice. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[180] N. Kaplan,et al. Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[181] S. Tashiro,et al. [Use of a lipid lymphographic agent, lipiodol, as a carrier of high molecular weight antitumor agent, smancs, for hepatocellular carcinoma]. , 1982, Gan to kagaku ryoho. Cancer & chemotherapy.
[182] T. Tsuruo,et al. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. , 1982, Cancer research.
[183] B. Sears,et al. Experimental methods in cancer therapeutics. , 1982, Journal of pharmaceutical sciences.
[184] H. Ringsdorf,et al. Antitumor activity of monomeric and polymeric cyclophosphamide derivatives compared with in vitro hydrolysis. , 1980, Cancer research.
[185] D. V. Von Hoff,et al. Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.
[186] E. Newlands,et al. Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients. , 1979, British Journal of Cancer.
[187] M Intaglietta,et al. Tissue perfusion inhomogeneity during early tumor growth in rats. , 1979, Journal of the National Cancer Institute.
[188] M. Tattersall,et al. Possible tumor localization of Tc-99m-labeled liposomes: effects of lipid composition, charge, and liposome size. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[189] J. Lown,,et al. The mechanism of the neocarzinostatin-induced cleavage of DNA. , 1978, Biochemical and biophysical research communications.
[190] R. Timpl,et al. Nature of the collagenous protein in a tumor basement membrane. , 1978, European journal of biochemistry.
[191] R. Juliano,et al. Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. , 1978, Biochemical pharmacology.
[192] G. Gregoriadis,et al. Fate of a liposome-associated agent injected into normal and tumour-bearing rodents. Attempts to improve localization in tumour tissues. , 1977, Life sciences.
[193] F. Davis,et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. , 1977, The Journal of biological chemistry.
[194] J. Driscoll,et al. The use of macromolecules as carriers of antitumor drugs. , 1977, European journal of cancer.
[195] M. Tattersall,et al. Properties of [99mTc] technetium-labelled liposomes in normal and tumour-bearing rats. , 1977, Biochemical Society transactions.
[196] S. Snyder,et al. Macromolecular naloxone: a novel long-acting polymer-bound drug. , 1976, Life sciences.
[197] P. Gullino,et al. Bulk transfer of fluid in the interstitial compartment of mammary tumors. , 1975, Cancer research.
[198] H. Ringsdorf. Structure and properties of pharmacologically active polymers , 1975 .
[199] P. Gullino,et al. Diffusion and convection in normal and neoplastic tissues. , 1974, Cancer research.
[200] S. Cooperband,et al. Antitumor effects of antibody-diphtheria toxin conjugates: use of hapten-coated tumor cells as an antigenic target. , 1972, Journal of the National Cancer Institute.
[201] B. Siegel,et al. Effect of irradiation on tumor microvascular permeability to macromolecules , 1972, Cancer.
[202] E. Potchen,et al. Pathophysiologic basis of soft tissue tumor scanning , 1971 .
[203] Mego Jl,et al. The Uptake of Labeled Proteins by Particulate Fractions of Tumor and Normal Tissues after Injection into Mice , 1965 .
[204] B. Sylvén,et al. Protein content and enzymatic assays of interstitial fluid from some normal tissues and transplanted mouse tumors. , 1960, Cancer research.
[205] J. Wolff,et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. , 1948, The New England journal of medicine.
[206] M. Wintrobe. Nitrogen mustard therapy. , 1948, The American journal of medicine.
[207] L. Goodman,et al. NITROGEN MUSTARD THERAPY: Use of Methyl-Bis(Beta-Chloroethyl)amine Hydrochloride and Tris(Beta-Chloroethyl)amine Hydrochloride for Hodgkin's Disease, Lymphosarcoma, Leukemia and Certain Allied and Miscellaneous Disorders , 1946 .
[208] P. Ehrlich,et al. Aus Theorie und Praxis der Chemotherapie , 1911 .